Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Prostate cancer
      • Bladder cancer
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • Media
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
    • Our annual accounts
    • Pelican Cancer Foundation – What next?
    • Support Us
    • Job opportunities
    • Partners
  • Workshops
    • TIPTOP
      • Workshops
      • TIPTOP – online resources
    • IMPACT
      • Workshops
      • IMPACT – online resources
      • IMPACT news
      • IMPACT partners and sponsors
    • SPECC
      • Workshops
      • Online resources
      • SPECC Partners and Sponsors
      • SPECC News
    • LOREC
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Prostate Cancer Research
      • Focal therapy and HIFU research
      • MRI research for prostate cancer
      • Prostate cancer colloquiums
      • FORECAST
      • Trachtomap
      • Papers of interest
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Bladder cancer research
      • PELT
      • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Jay’s story (bladder cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Prostate cancer
      • Our prostate cancer team
      • Prostate cancer treatment options
      • Pelican’s position
    • Bladder cancer
      • Blue light cystoscopy
      • Bladder cancer – useful contacts
    • Pseudomyxoma peritonei
    • Kidney cancer
      • Our kidney cancer team
      • Kidney cancer – useful contacts
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
        • How your donations are spent
    • Events and Challenges
    • Leaving a Legacy
    • Fundraising
      • Our fundraisers
      • Fundraising pack
      • Fundraising opportunities
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Charity of the Year partnerships
    • Pelican Film Society
  • Online Shop
  • Events
  • Contact us

The SPECC National Development Programme has successfully completed

December 15, 2017 by pelicanadmin

Significant Polyps and Early Colorectal Cancer – SPECC

Thanks to excellent guidance form our steering group (link) we started the SPECC National Development Programme workshops in London in November 2015.  Since then we have run 14 more workshops across England, Wales, Scotland and Ireland – making it an international programme.

The aims of the programme were to:

  • Define a significant polyp and identify an early colorectal cancer
  • Recognise a SPECC and how this is best achieved
  • Document and describe SPECC to better aid multi-disciplinary decision making
  • Plan carefully – ‘think twice and cut once’, making sure that the first shot it the best as these are ‘high value lesions’. Careful decision making about the use of biopsy and whether they add value. Take time and use regional and national resources, refer to experts – ‘another day, another endoscopist, another hospital’
  • Treatment – first treatment gives the best outcome. Low risk lesions can be safely removed endoscopically. MDT decision must include expert endoscopist

There was a core faculty of 10 with another 90 specialists joining the SPECC faculty to help with presentations and case studies.

1,237 clinicians attended a workshop over the 25 months that the programme ran.  These people came from 178 hospitals in England, Wales, Scotland, Northern Ireland and Ireland.  A third of those attending were consultant surgeons.

The programme was free for 6 core members of each colorectal MDT as long as this included a surgeon, gastroenterologist, pathologist, radiologist and specialist nurse.

Feedback:

‘Very interesting, well organised, fascinating’

‘Very high standard of talks & discussion’

‘Imaging and precision improves definitive treatment’

‘Think twice, cut once’

‘Super informative day – well done Pelican’

‘This was an excellent meeting and a lot of very interesting topics – valuable information for MDT management’

‘More awareness of polyp presentation and input of MDT in management decisions’

Achievement

Nearly every hospital throughout the UK and Ireland has now spent time considering this small but challenging cohort of patients who present with SPECC.  The multi-disciplinary members of the MDT have a greater awareness of the difficulties and uncertainties that SPECC present and will have more confidence within their MDT discussion about the local treatments available and where to refer if need be.

Finally – we would like to thank everyone for their help.  This programme was supported mainly by the generosity of Pelican charitable donations.  Hospitals that sent more than 6 delegates were charged £95 per person.  We are very grateful for industry sponsorship – Norgine supported all of the workshops, Exact Sciences, Medtronic and Applied Medical also attended a small number of meetings.

Filed Under: SPECC News, Uncategorized

Pelican Cancer FoundationFollow

Pelican Cancer Foundation
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
22 Dec

We would like to wish you all a very Merry Christmas and a peaceful New Year - especially to all the wonderful key workers, who will be working throughout. 🎄🥂🎁

Reply on Twitter 1341352794255593477Retweet on Twitter 1341352794255593477Like on Twitter 13413527942555934771Twitter 1341352794255593477
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
7 Dec

👏

Reply on Twitter 1335864743752589312Retweet on Twitter 1335864743752589312Like on Twitter 13358647437525893122Twitter 1335864743752589312
Pelican_CancerPelican Cancer Foundation@Pelican_Cancer·
5 Dec

Let loved ones know that you are thinking of them over the festive period and send a handwritten Christmas card. Order your Christmas cards from us at http://www.pelicancancer.org/shop. 🎄(Royal Mail’s latest recommended posting dates are 18th Dec (2nd Class) and 21st Dec (1st Class). 🎄

Reply on Twitter 1335126762079068160Retweet on Twitter 1335126762079068160Like on Twitter 1335126762079068160Twitter 1335126762079068160
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2021 · Outreach Pro Theme on Genesis Framework · WordPress · Log in